✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals
Market Cap
₹30,674 Cr.
P/E
109.85
About
Suven Pharmaceuticals Limited is a bio-pharmaceutical company that focuses on developing and manufacturing New Chemical Entity based Intermediates, Active Pharmaceutical Ingredients, Speciality Chemic… Read more
Suven Pharmaceuticals Limited is a bio-pharmaceutical company that focuses on developing and m… Read more
Low
598
52W Range
High
1360
  • Suven Pharma
  • Jubilant Pharmova
  • Syngene Internation.
  • TJI Pharma - API & CRAMS

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statementNew
Edit rows
Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • Number of ANDA's Filed in USA (.)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Corporate Actions
    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less
    FAQs on Suven Pharmaceuticals Ltd. Business

    Suven Pharmaceuticals Limited is a bio-pharmaceutical company specializing in the development and manufacturing of New Chemical Entity (NCE) based Intermediates, API, Speciality Chemicals, and formulated drugs for global pharmaceutical, biotechnology, and chemical companies.

    Suven Pharma major competitors are Jubilant Pharmova, Syngene Internation., Piramal Pharma, Hikal, Suven Life Sciences, Sun Pharma Adv. Res, Dishman Carbogen Amc.
    Market Cap of Suven Pharma is ₹30,656 Crs.
    While the median market cap of its peers are ₹5,142 Crs.

    Suven Pharma seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing
    2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Jun Sep Dec Mar Jun Mar Jun Sep Dec Dec
    Investor Presentation Jan Feb Mar Jun Sep Dec Jan Mar Jun Sep Nov Dec Mar May Jun Aug Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Mar Jun Sep Dec
    Conference Call SummaryCon Call Summary
    Discussions & Analysis
    Ideas Dashboard
    Timeline
    Watchlist
    Portfolio
    Alerts
    Research
    Stock Screener
    Market
    Raw Material